Literature DB >> 33707447

Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease.

Eleanor Sinclair1, Drupad K Trivedi1, Depanjan Sarkar1, Caitlin Walton-Doyle1, Joy Milne1, Tilo Kunath2, Anouk M Rijs3, Rob M A de Bie4, Royston Goodacre5, Monty Silverdale6, Perdita Barran7.   

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype. Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis. This study shows sebum can be used to identify potential biomarkers for PD.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33707447      PMCID: PMC7952564          DOI: 10.1038/s41467-021-21669-4

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  48 in total

1.  Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry.

Authors:  Warwick B Dunn; David Broadhurst; Paul Begley; Eva Zelena; Sue Francis-McIntyre; Nadine Anderson; Marie Brown; Joshau D Knowles; Antony Halsall; John N Haselden; Andrew W Nicholls; Ian D Wilson; Douglas B Kell; Royston Goodacre
Journal:  Nat Protoc       Date:  2011-06-30       Impact factor: 13.491

2.  Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.

Authors:  Constant V M Verschuur; Sven R Suwijn; Judith A Boel; Bart Post; Bas R Bloem; Johannes J van Hilten; Teus van Laar; Gerrit Tissingh; Alexander G Munts; Guenther Deuschl; Anthony E Lang; Marcel G W Dijkgraaf; Rob J de Haan; Rob M A de Bie
Journal:  N Engl J Med       Date:  2019-01-24       Impact factor: 91.245

Review 3.  CSF biomarkers in neurodegenerative diseases.

Authors:  Niklas Mattsson
Journal:  Clin Chem Lab Med       Date:  2011-02-09       Impact factor: 3.694

Review 4.  Parkinson's disease: mechanisms and models.

Authors:  William Dauer; Serge Przedborski
Journal:  Neuron       Date:  2003-09-11       Impact factor: 17.173

5.  Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.

Authors:  David S Goldstein; Courtney Holmes; Grisel J Lopez; Tianxia Wu; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2018-02-15       Impact factor: 4.891

6.  Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI).

Authors:  Lloyd W Sumner; Alexander Amberg; Dave Barrett; Michael H Beale; Richard Beger; Clare A Daykin; Teresa W-M Fan; Oliver Fiehn; Royston Goodacre; Julian L Griffin; Thomas Hankemeier; Nigel Hardy; James Harnly; Richard Higashi; Joachim Kopka; Andrew N Lane; John C Lindon; Philip Marriott; Andrew W Nicholls; Michael D Reily; John J Thaden; Mark R Viant
Journal:  Metabolomics       Date:  2007-09       Impact factor: 4.290

7.  Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study.

Authors:  Michelle M Mielke; Walter Maetzler; Norman J Haughey; Veera V R Bandaru; Rodolfo Savica; Christian Deuschle; Thomas Gasser; Ann-Kathrin Hauser; Susanne Gräber-Sultan; Erwin Schleicher; Daniela Berg; Inga Liepelt-Scarfone
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

8.  Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease.

Authors:  Shinji Saiki; Taku Hatano; Motoki Fujimaki; Kei-Ichi Ishikawa; Akio Mori; Yutaka Oji; Ayami Okuzumi; Takeshi Fukuhara; Takahiro Koinuma; Yoko Imamichi; Miho Nagumo; Norihiko Furuya; Shuko Nojiri; Taku Amo; Kazuo Yamashiro; Nobutaka Hattori
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

Review 9.  Overview of the Molecular Steps in Steroidogenesis of the GABAergic Neurosteroids Allopregnanolone and Pregnanolone.

Authors:  Jennifer J Liang; Ann M Rasmusson
Journal:  Chronic Stress (Thousand Oaks)       Date:  2018-12-19

10.  Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson's Disease Patients.

Authors:  Giovanni D'Andrea; Gilberto Pizzolato; Antonina Gucciardi; Matteo Stocchero; Giuseppe Giordano; Eugenio Baraldi; Alberta Leon
Journal:  Sci Rep       Date:  2019-04-16       Impact factor: 4.379

View more
  17 in total

1.  An integrated analysis and comparison of serum, saliva and sebum for COVID-19 metabolomics.

Authors:  Matt Spick; Holly-May Lewis; Cecile F Frampas; Katie Longman; Catia Costa; Alexander Stewart; Deborah Dunn-Walters; Danni Greener; George Evetts; Michael J Wilde; Eleanor Sinclair; Perdita E Barran; Debra J Skene; Melanie J Bailey
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

2.  Metabolomics of blood reveals age-dependent pathways in Parkinson's Disease.

Authors:  Nicola D'Ascenzo; Emanuele Antonecchia; Antonella Angiolillo; Victor Bender; Marco Camerlenghi; Qingguo Xie; Alfonso Di Costanzo
Journal:  Cell Biosci       Date:  2022-07-06       Impact factor: 9.584

3.  Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans.

Authors:  Gregory D Scott; Miranda M Lim; Matthew G Drake; Randy Woltjer; Joseph F Quinn
Journal:  Mov Disord       Date:  2021-05-03       Impact factor: 10.338

Review 4.  The Potential of Metabolomics in Biomedical Applications.

Authors:  Vanessa Gonzalez-Covarrubias; Eduardo Martínez-Martínez; Laura Del Bosque-Plata
Journal:  Metabolites       Date:  2022-02-19

Review 5.  Metabolomics and health: from nutritional crops and plant-based pharmaceuticals to profiling of human biofluids.

Authors:  Andrey S Marchev; Liliya V Vasileva; Kristiana M Amirova; Martina S Savova; Zhivka P Balcheva-Sivenova; Milen I Georgiev
Journal:  Cell Mol Life Sci       Date:  2021-08-19       Impact factor: 9.261

6.  Artificial Intelligent Olfactory System for the Diagnosis of Parkinson's Disease.

Authors:  Wei Fu; Linxin Xu; Qiwen Yu; Jiajia Fang; Guohua Zhao; Yi Li; Chenying Pan; Hao Dong; Di Wang; Haiyan Ren; Yi Guo; Qingjun Liu; Jun Liu; Xing Chen
Journal:  ACS Omega       Date:  2022-01-26

7.  A Retrospective Metabolomics Analysis of Gamma-Hydroxybutyrate in Humans: New Potential Markers and Changes in Metabolism Related to GHB Consumption.

Authors:  Tingting Wang; Kirstine L Nielsen; Kim Frisch; Johan K Lassen; Camilla B Nielsen; Charlotte U Andersen; Palle Villesen; Mette F Andreasen; Jørgen B Hasselstrøm; Mogens Johannsen
Journal:  Front Pharmacol       Date:  2022-03-03       Impact factor: 5.810

8.  Circulating CircRNAs Panel Acts as a Biomarker for the Early Diagnosis and Severity of Parkinson's Disease.

Authors:  Lingling Zhong; KeJu Ju; Ainian Chen; Hua Cao
Journal:  Front Aging Neurosci       Date:  2021-07-01       Impact factor: 5.750

9.  Application of Sebum Lipidomics to Biomarkers Discovery in Neurodegenerative Diseases.

Authors:  Stefania Briganti; Mauro Truglio; Antonella Angiolillo; Salvatore Lombardo; Deborah Leccese; Emanuela Camera; Mauro Picardo; Alfonso Di Costanzo
Journal:  Metabolites       Date:  2021-11-29

Review 10.  Lipotoxicity Downstream of α-Synuclein Imbalance: A Relevant Pathomechanism in Synucleinopathies?

Authors:  Arati Tripathi; Saranna Fanning; Ulf Dettmer
Journal:  Biomolecules       Date:  2021-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.